Publications
- Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial2015 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry2015 | First Faculty of Medicine
- Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines2014 | First Faculty of Medicine, Second Faculty of Medicine
- The Role of Cytochromes P450 and Aldo-Keto Reductases in Prognosis of Breast Carcinoma Patients2014 | First Faculty of Medicine, Second Faculty of Medicine
- Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression2013 | First Faculty of Medicine, Second Faculty of Medicine
- Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas2012 | First Faculty of Medicine, Second Faculty of Medicine
- Diffuse large B-cell lymphomas: heterogeneous origin and prognosis from the view of contemporary diagnostics2003 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport
- Integrative analysis of mRNA and miRNA expression profiles and somatic variants in oxysterol signaling in early-stage luminal breast cancer2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States2023 | Faculty of Social Sciences
Loading network view...